Company Compugen to start anti-cancer clinical trials
The company Compugen is commencing recruitment for the clinical trial of the drug COM701 in combination with BMS-986207 and Nivolumab in subjects with advanced solid tumors.
The conditions are endometrial neoplasms, ovarian cancer and solid tumor.
A new clinical trial of anti-cancer drug is recruiting patients in the following locations: Michigan and Texas in United States.
The trial officially began on the 31st August and is planning to complete on December 2023.
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of the drug.
The population that can be enrolled into this study includes the patients with histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all available standard therapy or is not a candidate for the available standard therapy.
Patients with the following pathologies:
- active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of the drug;
- symptomatic interstitial lung disease or inflammatory pneumonitis;
- history of immune-related events that lead to immunotherapy treatment discontinuation;
- untreated or symptomatic central nervous system (CNS) metastases
are excluded from participation.
Bristol-Myers Squibb is the collaborator in this clinical trial.
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel.
